Key result
Labetalol achieves faster blood pressure control by ~1 day compared to methyldopa.
Why the study?
Labetalol and Alpha-methyldopa are commonly used antihypertensive agents in pregnancy, yet their comparative effectiveness in primigravida requires further clarification.
Does labetalol improve time to blood pressure control and reduce severe pregnancy-induced hypertension compared to alpha-methyldopa in primigravida?
RCT (n=100)
Randomized into two equal groups
No
Does labetalol improve time to blood pressure control and reduce severe pregnancy-induced hypertension compared to alpha-methyldopa in primigravida?
Labetalol provides faster blood pressure control and reduces the incidence of severe pregnancy-induced hypertension compared to alpha-methyldopa in primigravida, with a comparable safety profile.
Labetalol may accelerate BP control in PIH; hypothesis-generating and requires larger trials before practice change.
Background: Pregnancy-induced hypertension (PIH) continues to be a significant reason for maternal and perinatal morbidity. Labetalol and Alpha-methyldopa are commonly used antihypertensive agents in pregnancy, yet their comparative effectiveness in primigravida requires further clarification.Aim: To compare the safety and effectiveness of Labetalol versus Alpha-methyldopa in controlling PIH among primigravida.Methods: Prospective research was performed on 100 primigravida with PIH attending El-Hussien Hospital from January 2024 to July 2025. Patients were randomized into two equal groups: Group 1 received Labetalol (100 mg twice daily, titrated up to 2400 mg/day) and Group 2 received Alpha-methyldopa (250 milligrams twice daily, up to 3 g/day). Blood pressure (BP), time to BP control, required doses, maternal side effects, fetal well-being, and pregnancy complications were monitored. Statistical analyses included t-tests, Mann–Whitney U, and chi-square tests, with significance set at p<0.05.Results: Baseline characteristics were comparable between groups (p>0.05). Labetalol achieved significantly faster BP control than Alpha-methyldopa (3.87±1.14 vs. 4.96±1.36 days; p<0.001). Post-treatment diastolic BP was significantly lower in the Labetalol group (p<0.001). Severe PIH was less frequent with Labetalol (4% vs. 20%; p=0.013). Insignificant variances were found regarding proteinuria, eclampsia, fetal distress, or maternal side effects (p>0.05). Both drugs were generally well tolerated.Conclusion: Labetalol provides faster and more effective BP control than Alpha-methyldopa, with a lower incidence of severe PIH, while both drugs demonstrate similar safety and fetal outcomes. Labetalol may be favored as a first-line agent for PIH in primigravida requiring prompt BP control.
No takes yet. Share an insight, caveat, or question.
Ashoush et al. (2026) conducted an RCT in Pregnancy-induced hypertension (PIH) (n=100). Labetalol vs. Alpha-methyldopa (250 mg twice daily, up to 3 g/day) was evaluated on Time to blood pressure control (days) (p=<0.001). Labetalol achieved significantly faster blood pressure control than alpha-methyldopa (3.87 vs 4.96 days; P<0.001) and resulted in a lower frequency of severe PIH (4% vs 20%; P=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: